Jeil Pharm (002620.KS) stock: key figures, P/E, revenue and dividend

Health Care · Pharmaceuticals · South Korea · ISIN KR7002620003

Price
6,520.00 KRW
Market cap
100.09 bn KRW
P/E (2025)
–
P/S (2025)
0.15
Dividend yield
1.07 %
Net margin
2.23 %
Return on equity (ROE)
3.12 %
Return on assets (ROA)
1.67 %

Jeil Pharm financials

Fiscal year20242025
Revenue779.82 bn KRW657.61 bn KRW
Gross profit206.52 bn KRW253.50 bn KRW
Operating income-11.18 bn KRW38.99 bn KRW
EBIT-52.75 bn KRW46.86 bn KRW
Net income-51.16 bn KRW14.64 bn KRW

Full history since 2001, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

Sign up for freeOpen interactive view

About Jeil Pharm

Jeil Pharma Holdings Inc manufactures and sells ingredients of drugs, incrementally modified drugs, and generic drugs in South Korea. The company offers active pharmaceutical ingredients in the areas of antibiotics, gastrointestinal, cardiovascular, neuropsychiatry, oncology, endocrinology, urology, antiviral, and antihistamines, as well as patch products. It also provides finished dosage forms in the areas of anti-bacteria and anti-fungal, anti-virus, cardiovascular, endocrinology, neurology, gastrointestinal, urology, oncology, anti-histamine, rheumatology, respiratory, otolaryngological, heaptic, laxatives, and purgatives. The company exports its products to approximately 40 countries in the Association of Southeast Asian Nations, Central and South America, Africa, etc. The company was founded in 1959 and is headquartered in Seoul, South Korea.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.